Ensuring Detection of All HIV Groups and Variants
Reactivity in HIV-1 (Groups M and O) and HIV-2 Positive Samples
Results obtained with GS HIV-1/HIV-2 PLUS O EIA
| Group | Number Reactive | Percent Reactive |
| Known HIV-1 Positive* (N = 1002) | 1002 | 100% |
| Known HIV-2 Positive† (N = 302) | 302 | 100% |
| Known HIV-1 Group O Positive‡ (N = 77) | 77 | 100% |
* Included 313 AIDS patients, 490 known HIV-1 positive samples from the U.S., and 199 known HIV-1 positive samples from non-U.S.
countries. [Australia, New South Wales (N = 36), Central African Republic (N = 40), Ghana (N = 5), Kenya (N = 3), Nigeria (N = 46),
Sierra Leone (N = 40), Thailand (N = 21), Zimbabwe (N = 8)].
† HIV-2 samples were repeatedly reactive on an HIV-2 EIA, positive on an HIV-2 Western blot, and indeterminate or negative on an
HIV-1 Western blot.
‡ Samples were characterized as HIV-1 group O by serotype and/or genotype.
Closing the Serological Window
Reactivity on 50 HIV-1 Seroconversion Panels
Results Obtained with GS HIV-1/HIV-2 PLUS O EIA
| Comparison | HIV-1/HIV-2 PLUS O Equivalent | HIV-1/HIV-2 PLUS O More Sensitive | HIV-1/HIV-2 PLUS O Less Sensitive |
| Licensed Kit #1 | 12/46* (26%) | 34/46* (74%) | 0 (0%) |
| Licensed Kit #2 | 35/50 (70%) | 9/50 (18%) | 6/50 (12%) |
| Licensed Western Blot | 13/50 (26%) | 37/50 (74%) | 0 (0%) |
* Four of the 50 seroconversion panels did not have test results with the licensed HIV-1/HIV-2 EIA Kit # 1 and are no longer available
for testing.